Current use of dendritic cells in cancer immunotherapy

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Lopez, JA
Hart, DNJ
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2002
Size
File type(s)
Location
License
Abstract

Dendritic cells (DCs) initiate and direct the immune response. Their inability to detect danger signals from transformed cells and to generate an effective immunological response may allow cells with a malignant phenotype to evolve into cancers. This defect can be corrected for many cancer types and the immune response boosted to eliminate malignant cells by means of DC-based vaccines/therapies. Rapid advances in our understanding of basic DC physiology and improved methods for DC isolation have made clinical application of DC therapy practical and encouraging phase I/II results are emerging.

Journal Title
Conference Title
Book Title
Edition
Volume

4

Issue

1

Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© 2002 Pharma Press. After all reasonable attempts to contact the copyright owner, this work was published in good faith in interests of the digital preservation of academic scholarship. Please contact copyright@griffith.edu.au with any questions or concerns.

Item Access Status
Note
Access the data
Related item(s)
Subject

Biomedical and clinical sciences

Tumour immunology

Persistent link to this record
Citation
Collections